Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
Clinical vertebral fractures · postmenopausal women with a higher risk for fracturesa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐vertebral fractures · postmenopausal women with a higher risk for fracturesa
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (low certainty).
1 finding from 1 review
RR 1.07 [0.72, 1.58]
Studies not reported
Low
Hip Fracture · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes hip fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.93 [0.17, 5.19]
Studies not reported
Very low
Woman's perception of pain (as defined by trialists) · Pregnant women with varicose veins and leg oedema in pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complications associated with varicose veins and leg oedema (venous leg ulcer) · Pregnant women with varicose veins and leg oedema in pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptoms associated with varicose veins and oedema · Pregnant women with varicose veins and leg oedema in pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in event‐free survival compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).
1 finding from 1 review
Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in hypersensitivity compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).
1 finding from 1 review
Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… probably leads to lower pancreatitis compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).
1 finding from 1 review
Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in thromboembolism compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).
1 finding from 1 review
Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in osteonecrosis compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).
1 finding from 1 review
Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… probably leads to lower asparaginase‐associated toxicity compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).
1 finding from 1 review
Kidney recovery functionby KRT: continuous and intermittent KRT · AKI
Subgroup analyses: early showed no clear difference in kidney recovery functionby KRT: continuous and intermittent KRT compared with standard initiation of kidney replacement therapy (KRT) (moderate certainty).
1 finding from 1 review
Duration of respiratory support (intermittent positive pressure ventilation or continuous positive airway pressure; hours). · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Proportion of children achieving 14 consecutive dry nights by the end of treatment · children with nocturnal enuresis
It is very uncertain whether alarm changes proportion of children achieving 14 consecutive dry nights by the… compared with other types of alarm (very low certainty).
1 finding from 1 review
Failure of treatment ‐ death or intermittent positive‐pressure ventilation (IPPV) before hospital discharge · preterm infants with respiratory distress for initial respiratory support
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intermittent and absolute claudication distances · people with critical limb ischaemia due to non‐reconstructable peripheral arterial disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intermittent Prophylactic Treatment for malaria · pregnant women
1 finding from 1 review